Impact of Gleason Pattern 5 on outcomes of patients with prostate cancer and iodine-125 prostate brachytherapy
Background: The Gleason grading system is a powerful predictor of prostate cancer (PCa) prognosis. Gleason scores (GS) of 8–10 are considered as a single high-risk grade category, and Gleason Pattern 5 (GP5) predicts biochemical recurrence. We report the clinical outcomes of patients treated with 12...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2016-12-01
|
| Series: | Prostate International |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2287888216300514 |
| _version_ | 1827838692574625792 |
|---|---|
| author | Tomoyuki Makino Sotaro Miwa Kiyoshi Koshida |
| author_facet | Tomoyuki Makino Sotaro Miwa Kiyoshi Koshida |
| author_sort | Tomoyuki Makino |
| collection | DOAJ |
| description | Background: The Gleason grading system is a powerful predictor of prostate cancer (PCa) prognosis. Gleason scores (GS) of 8–10 are considered as a single high-risk grade category, and Gleason Pattern 5 (GP5) predicts biochemical recurrence. We report the clinical outcomes of patients treated with 125I prostate brachytherapy for clinically localized PCa and prognosis in the presence or absence of GP5.
Methods: We enrolled 316 patients with T1c–T2N0M0 PCa and undergoing prostate brachytherapy treatment. All patients were followed up for ≥ 1 year. The primary endpoint was biochemical recurrence-free survival. Biochemical recurrence was defined by the Phoenix criteria. Survival curves were calculated by the Kaplan–Meier method, and the prognostic impact of biochemical recurrence was analyzed using a Cox proportional hazards model.
Results: The 5-year biochemical recurrence-free survival rate for all patients was 95.2%, and according to the D’Amico risk classification criteria, the rates were 98.7% for patients in low-risk, 96.9% in intermediate-risk, and 81.1% in high-risk groups (P < 0.0001). The 5-year biochemical recurrence-free survival rates for patients with GS8 or GS9–10 were 87.7% and 61.5%, respectively (P = 0.0057). Multivariate analysis found that GS and clinical T stage were independent predictors of biochemical recurrence.
Conclusions: The presence of GP5 in GS9–10 prostate cancer has a worse prognosis than GS8 prostate cancer in the absence of GP5 for patients undergoing prostate brachytherapy. |
| first_indexed | 2024-03-12T07:09:44Z |
| format | Article |
| id | doaj.art-f71287af1d034b6ebe161724aab5621f |
| institution | Directory Open Access Journal |
| issn | 2287-8882 |
| language | English |
| last_indexed | 2024-03-12T07:09:44Z |
| publishDate | 2016-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Prostate International |
| spelling | doaj.art-f71287af1d034b6ebe161724aab5621f2023-09-02T23:13:26ZengElsevierProstate International2287-88822016-12-014415215510.1016/j.prnil.2016.10.001Impact of Gleason Pattern 5 on outcomes of patients with prostate cancer and iodine-125 prostate brachytherapyTomoyuki MakinoSotaro MiwaKiyoshi KoshidaBackground: The Gleason grading system is a powerful predictor of prostate cancer (PCa) prognosis. Gleason scores (GS) of 8–10 are considered as a single high-risk grade category, and Gleason Pattern 5 (GP5) predicts biochemical recurrence. We report the clinical outcomes of patients treated with 125I prostate brachytherapy for clinically localized PCa and prognosis in the presence or absence of GP5. Methods: We enrolled 316 patients with T1c–T2N0M0 PCa and undergoing prostate brachytherapy treatment. All patients were followed up for ≥ 1 year. The primary endpoint was biochemical recurrence-free survival. Biochemical recurrence was defined by the Phoenix criteria. Survival curves were calculated by the Kaplan–Meier method, and the prognostic impact of biochemical recurrence was analyzed using a Cox proportional hazards model. Results: The 5-year biochemical recurrence-free survival rate for all patients was 95.2%, and according to the D’Amico risk classification criteria, the rates were 98.7% for patients in low-risk, 96.9% in intermediate-risk, and 81.1% in high-risk groups (P < 0.0001). The 5-year biochemical recurrence-free survival rates for patients with GS8 or GS9–10 were 87.7% and 61.5%, respectively (P = 0.0057). Multivariate analysis found that GS and clinical T stage were independent predictors of biochemical recurrence. Conclusions: The presence of GP5 in GS9–10 prostate cancer has a worse prognosis than GS8 prostate cancer in the absence of GP5 for patients undergoing prostate brachytherapy.http://www.sciencedirect.com/science/article/pii/S2287888216300514BrachytherapyGleason pattern 5Iodine-125Prostate cancer |
| spellingShingle | Tomoyuki Makino Sotaro Miwa Kiyoshi Koshida Impact of Gleason Pattern 5 on outcomes of patients with prostate cancer and iodine-125 prostate brachytherapy Prostate International Brachytherapy Gleason pattern 5 Iodine-125 Prostate cancer |
| title | Impact of Gleason Pattern 5 on outcomes of patients with prostate cancer and iodine-125 prostate brachytherapy |
| title_full | Impact of Gleason Pattern 5 on outcomes of patients with prostate cancer and iodine-125 prostate brachytherapy |
| title_fullStr | Impact of Gleason Pattern 5 on outcomes of patients with prostate cancer and iodine-125 prostate brachytherapy |
| title_full_unstemmed | Impact of Gleason Pattern 5 on outcomes of patients with prostate cancer and iodine-125 prostate brachytherapy |
| title_short | Impact of Gleason Pattern 5 on outcomes of patients with prostate cancer and iodine-125 prostate brachytherapy |
| title_sort | impact of gleason pattern 5 on outcomes of patients with prostate cancer and iodine 125 prostate brachytherapy |
| topic | Brachytherapy Gleason pattern 5 Iodine-125 Prostate cancer |
| url | http://www.sciencedirect.com/science/article/pii/S2287888216300514 |
| work_keys_str_mv | AT tomoyukimakino impactofgleasonpattern5onoutcomesofpatientswithprostatecancerandiodine125prostatebrachytherapy AT sotaromiwa impactofgleasonpattern5onoutcomesofpatientswithprostatecancerandiodine125prostatebrachytherapy AT kiyoshikoshida impactofgleasonpattern5onoutcomesofpatientswithprostatecancerandiodine125prostatebrachytherapy |